Medical device maker Medtronic Inc. resolved the Competition Bureau's concern that its acquisition of competitor Covidien PLC would reduce competition for the supply of drug-coated balloon catheters for the treatment of peripheral artery disease by agreeing to sell Covidien's drug-coated balloon catheter business to Spectanetics. Medtronic and Covidien signed a consent agreement with the Bureau.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.







